

Bioconjugated Plasmonic Nanoparticles for Enhanced Skin Penetration.

David Alba-Molina, Juan J. Giner-Casares,* Manuel Cano*

Department of Physical Chemistry and Applied Thermodynamics, Institute of Nanochemistry (IUNAN), University of Córdoba, Campus Universitario de Rabanales, Ed. Marie Curie, Córdoba, Spain E-14014.

*E-mail: jjginer@uco.es; q82calum@uco.es

Abstract

Plasmonic nanoparticles (NPs) are one of the most promising and studied inorganic nanomaterials for different biomedical applications. Plasmonic NPs provide excellent biocompatibility, long-term stability against physical and chemical degradation, relevant optical properties, well-known synthesis methods and tuneable surface functionalities. Herein, a review of recently reported bioconjugated plasmonic NPs using different chemical approaches and loading cargoes (such as drug, gene, and proteins) for enhancement of transdermal delivery across biological tissues is presented. The main aim is the understanding of the interaction of the complex skin structure with biomimetic plasmonic NPs. This knowledge not only plays an important role for enhancing transdermal delivery of pharmaceutical formulations but also for controlling undesired skin penetration of industrial products, such as cosmetic, sunscreen formulations and any other mass-usage consumable containing nanoparticles.

Keywords: Plasmonic nanoparticles, transdermal drug delivery, bioconjugated nanomaterials, skin penetration, gold and silver nanoparticles.

1. Introduction.

This review is focused on plasmonic nanoparticles (NPs) throughout the whole range of inorganic NPs. Plasmonic NPs are composed of colloidal particles of noble metals which present a characteristic surface plasmon resonance (SPR) band. The SPR band is attributed to the electric field of incident light, which induces coherent oscillation of conduction band electrons of the positively charged metallic core (**Figure 1**). These optical and electronic properties of the plasmonic NPs can be easily tuned by changing the size, shape, and surface chemistry.[1–3]

Among the different plasmonic NPs, this work is mainly focus on Au and Ag-based NPs, which are considered as non-allergenic compounds that should not induce cytotoxicity, therefore being highly attractive for biomedical applications.[4, 5] In addition to their inherent characteristic properties of nanometric materials, such as small size and high surface area-to-volume, the surface chemistry of the AuNPs can be easily modified through the covalent Au-S bond.[6, 7] These features have made AuNPs one of the most widely used nanomaterials both in technological and in biomedical applications, such as electronics,[8, 9] catalysis,[10, 11] sensory probes,[12, 13] plasmonic photothermal therapy,[14, 15] targeted drug delivery carrier,[16, 17] contrast agents in x-ray imaging and computed tomography for cancer diagnosis,[18, 19] to name only a few. AgNPs display an inherent antimicrobial capacity against bacteria, viruses, and other eukaryotic microorganisms.[20, 21] For this, silver compounds have been historically used in fields to prevent microbial growth, in wound care and in products such as odour-reducing clothing, acne creams, and face masks.[22, 23]




Figure 1. Schematic representation of Surface Plasmon Resonance (SPR) band in spherical (A) and rod-shape (B) plasmonic NPs.

Topical administration of compounds presents several advantages against other routes, such as oral, nasal, and intravenous administration. Transdermal delivery overcomes the first-pass hepatic metabolism and can reduce harmful side-effects.[24–26] However, skin is a complex multilayer structure (mainly composed of epidermis, dermis, and hypodermis) with highly impermeable barriers to most molecules on the basis of particle size, water-solubility and surface charge.[24] In addition, hair follicles have also been explored as a more permeable transporting channel for transdermal drug delivery.[27–29] An excellent review of the influence of size on the penetration of both metal and non-metal NPs through skin was published by Larese Filon et al.[30]

Bare NPs do not overcome skin barriers efficiently as reported by Núñez-Lozano et al.[31] In other words, non-functionalized NPs constitute poor transdermal drug delivery systems.[32, 33] Therefore, many efforts have been made to enhance the skin penetration of the NPs through purposefully designed chemical functionalization with biomolecules and bioinspired polymers to form biomimetic NPs and providing additional abilities in skin penetration. Herein we aim at compiling the latest advances on the development of different approaches to fabricate bioconjugated plasmonic NPs for enhanced skin penetration. This review is organized as follow: Firstly, the influence of the key parameters on the skin penetration of non-bioconjugated plasmonic NPs is discussed and, secondly, some of the more recently reported bioconjugated plasmonic NPs for enhanced skin penetration is presented.

2. Influence of key-parameters on the skin penetration of non-bioconjugated plasmonic NPs.

The ability of plasmonic NPs for skin penetration can be tuned by controlling their core-composition, particle-size and -shape, surface charge, water solubility and the functionalization strategy, including both capping-ligands and delivered cargoes, i.e., drugs, genes, and proteins. Relevant examples of the most prominent studies in each of these parameters are mentioned below:

2.1. Core composition (noble metal type).

The literature indicates a significant difference in terms of skin penetration behaviour between organic and inorganics NPs. There are also significant differences for skin

internalization depending on its chemical composition (i.e. TiO₂, SiO₂, ZnO, FeO, CdSe, Pd, etc.) within the latter group, as previously reported by Larese Filon et al.,[30] In the case of plasmonic NPs, the in vitro penetration of AgNPs through intact human skin samples has been reported for several authors (with particle size in a narrow range between 19 and 25 nm), suggesting that ions release is the most feasible penetration mechanism.[34, 35] Whilst for AuNPs, its penetration through intact human skin samples has been demonstrated by several authors (size ~12 nm), although the penetration process is unclear, being discarded the ions release mechanism. The absence of Au ions in physiological solutions of AuNPs has been reported, indicating its higher long-term colloidal stability than AgNPs.[30, 36] This high stability could explain the absence or low cytotoxicity of this type of plasmonic NPs.

2.2. Particle size-effect.

Although the literature shows contradictory results in this issue, skin penetration of NPs is considered a size-dependent process.[30] Note that the stability of the NP coating should be taken into account because it plays a key role both in the interaction between skin and NP core (see section 2.4), and between the NPs (i.e. steric stabilization) by avoiding the particle aggregation when they come into contact with the stratum corneum and constituent cells of the skin, mainly keratinocytes.

A representative study showing that AuNPs penetrate through intact skin samples in a size-dependent manner was reported by Sonavane et al., who analysed the penetration of 15, 102 and 198 nm citrate-capped AuNPs, with spherical shapes and surface negative charge, through rat-skin and rat-intestine using Franz diffusion cells.[37] The smallest AuNPs showed higher permeation than the larger particles. In a similar study with rats, Raju and co-workers reported that 22 nm citrate-capped AuNPs showed higher penetration than 105 and 186 nm particles across the thick stratum corneum of the plantar rat skin .[38]

A key aspect on the experimental design for assessing the skin penetration of plasmonic nanoparticles is the in vitro or in vivo model used to perform the analysis. Indeed, the choice of biologically relevant and realistic model for studying the biological effect of nanoparticles is a comparatively unexplored field.[39] Although rat, mouse and rabbits have been extensively used for these penetration studies, pig skin is probably the most similar animal model to the human skin.[40] Pig and human skin are structurally very

similar in thickness and dermal-epidermal thickness ratio. Hair follicles and blood vessel patterns in the skin are also similar. In addition, the thickness of the human skin varies considerably as a function of the body region, gender and age, among other factors. For this reason, the results obtained are quite different depending on the used in vivo model, and even depending on the part used of human body. An interesting study on porcine skin using AgNPs was reported by Samberg and co-workers, who evaluated the in vitro and in vivo toxicity of eight different commercial AgNPs supplied by nanoComposix (San Diego, CA), such as unwashed/uncoated (diameter of 20, 50, and 80 nm), washed/uncoated (20, 50, and 80 nm), and carbon-coated (25 and 35 nm).[22] They observed that the toxicity of AgNPs in HEKs was significantly influenced by the residual contaminants in their supernatant, and that AgNPs themselves may not be responsible for an increase in cell mortality. The degradation of AgNPs within the cell was also considered as a source for reactive oxygen species that would be damaging to cell machinery and DNA.[41]

Obviously, human skin would be ideal to perform in vitro skin penetration analysis. In 2012, Liu et co-workers investigated the in vitro penetration and metabolic effects of 10, 30 and 60 nm citrate-capped AuNPs within viable excised human abdominal skin after 24-hour exposure.[42] Using multiphoton tomograph-fluorescence lifetime imaging microscopy, they only observed penetration into the stratum corneum, without significant penetration into the lower layers. They demonstrated that viable human skin resists permeation of small NPs, which had been previously reported to penetrate deeply in other animal skin models.

Note that a remarkable attempt to categorize the size range with its skin penetration ability was carried out by Larese Filon et al.[30] They suggested that: (i) NPs smaller than 4 nm can both penetrate and permeate intact skin, (ii) NPs in the size range between 4 and 20 nm can permeate both intact and damaged skin, (iii) NPs with diameter between 21 and 45 nm can penetrate and permeate damaged skin, and (iv) NPs higher than 45 nm can neither penetrate nor permeate the skin. They also considered the hydrodynamic diameter of the NPs, which is an important parameter of the colloidal particles that can be greatly affected both for the ligand-coating and the electrolyte composition of the colloidal solution.[43]

2.3. Shape-effect.




Figure 2. Schematic representation of plasmonic NPs with different geometries (A) and of the human skin layers (B).

Despite the enormous literature reporting protocols for the synthesis of plasmonic NPs with different morphologies, such as rod, triangle, bipyramid, star, cube and others, [44–46] as well as the important effect on the resulting NP flow characteristic that alters cell membrane interactions, macrophage uptake and circulating lifetimes,[47–49] research papers investigating the influence of the NPs shape on skin penetration has been rarely reported (**Figure 2**). This fact could be attributed mainly to the resulting higher size (e. g. > 45 nm) and to the lower resulting long-term stability of the anisotropic NPs (i.e. non-spherical geometries). Only comparative studies between spherical and rod-shape AuNPs can be found in the literature. A relevant study was reported by Fernandes et al.,[50] showing from their culture experiments in mouse and human skin samples than the percentage of PEG-capped Au-nanorods (with an aspect ratio 2.8 ± 0.5) found in all samples was higher than the one obtained for the similar PEG-capped spherical 15 ± 1 nm AuNPs. These results were obtained both for positively and for negatively surface charged NPs, suggesting the great influence of the NP-shape on its penetration capacity. In the case of AgNPs, Tak and co-workers reported a skin penetration study of differently shaped NPs using both in vitro and in vivo models.[51] They used spherical, rod-shape

and triangular AgNPs with similar hydrodynamic diameter (~50 nm) and zeta-potential (+ 30 mV) to perform in vitro analysis on ultra-thin mouse skin section by Franz cell system, and in vivo analysis on hairless mice. In agreement with previous results for AuNPs, they showed that rod-shape AgNPs presented higher permeability index than the spherical and triangular ones. They concluded that different shapes of AgNPs may exhibit diverse antimicrobial activities and skin penetration capabilities depending upon their active metallic facets.

2.4. Influence of the capping-ligand, including surface-chemistry and -charge.




Figure 3. Representative stabilizing ligand for plasmonic NPs.

Another important parameter that greatly affects the skin penetration rate of the NPs is the surface charge and chemistry, which is directly associated with the stabilizing ligand composition and the type of the metal-ligand bonding interaction. **Figure 3** summarizes the most frequently found capping ligands, including the type of interaction with the metallic core. Citrate is the main ligand for the synthesis of plasmonic NPs,[52, 53] and

it is the most widely reported. Despite the resulting water-soluble NPs present a good long-term stability, with a negatively charged surface due to their carboxylate groups, the NPs tended to aggregate easily in contact with the skin (specially for the smallest sizes) due to their relatively weak metal-ligand interaction.[7] Labouta and co-workers showed that water-soluble spherical-shape 15 nm citrate-capped AuNPs tended to aggregate on the superficial stratum corneum.[54] In this study, the penetration rate of hydrophilic 15 nm citrate-capped AuNPs versus hydrophobic 6 nm dodecanethiol-capped AuNPs was also compared, showing that non-water-soluble particles penetrated through the stratum corneum and into viable epidermal layers of human skin. This enhance on the skin penetration using dodecanethiol as capping ligand could be attributed to: (a) The stronger Au-S binding interaction, which avoid aggregation of NPs in contact with the stratum corneum, and (b) to the solubility in organic solvent (i.e. toluene) that could facilitate the interaction with the cell membranes. A related study from the same research group compared the different penetration rate through human skin of two water-soluble AuNPs (15 nm citrate- and 6 nm lecithin-capped) against two toluene-solved ones (6 nm dodecanethiol- and cetrimide-capped).[55] They concluded that the vehicle (toluene-versus-water) had a minimal effect on skin penetration of AuNPs.

Not only should the bond strength of the metal-ligand interaction be considered but also the coating thickness and the surface coverage degree. Previous studies have demonstrated that polymeric capping ligands as poly(N-vinyl-2-pyrrolidone) (PVP) are well suited to stabilize the surface of AuNPs for skin penetration, despite of the weak metal-ligand interactions via pyrrolidone groups.[56] Huang and co-workers showed that water-soluble 5 nm PVP-capped AuNPs with spherical shape were mice skin permeable. They attributed this effect to the nano-bio interaction with skin lipids and the consequent induction of transient and reversible openings on the stratum corneum. In addition, they highlighted that co-administration of these PVP-capped AuNPs with protein drugs could enhance transdermal drug delivery.[56]

Additionally, the capping ligand confers a given surface charge to the NPs, which greatly affects to the resulting skin penetration rate. For instance, positively charged drug carriers, such as dendrimers and liposomes, are well-known to induce greater drug delivery in the skin.[57, 58] In this direction, Fernandes et al. showed that positively charged PEG-capped AuNPs were found in the skin in 2-6 folds higher amount that their negative counterparts.[50] These results were obtained both for spherical- and for rod-shaped NPs,

and were in agreement with the enhanced skin permeation of cationic liposomes, which was attributed to the “Donnan exclusion effect” and to the better interaction of cationic particles with the negatively charged skin cells.[59] Furthermore, in this study, they also showed that AuNPs functionalized with cell penetrating peptides (CPPs) TAT and R7 were found in the skin in larger quantities than PEGylated AuNPs, demonstrating that bioconjugation greatly enhance the skin penetration rate.[50]

On an alternative strategy, Lee and co-workers investigated the influence of the surface charge of Au-nanorods on skin penetration using layer-by-layer (LbL) polyelectrolyte coating technique.[60] They observed that negatively charged CTAB/PSS-capped Au-nanorods penetrated more rapidly through the skin than the positively ones (CTAB- and CTAB/PSS/PDADMAC-capped). For this, three different multi-layer coated Au-nanorods with particle size of 18 x 40 nm were used: Two positively charged, CTAB- and CTAB/PSS/PDADMAC-capped, and one negatively charged, CTAB/PSS-capped. These surprising results were attributed to both the aggregation of the positively charged Au-nanorods on the stratum corneum and the adsorption of proteins released from the dermis layer to the surface of Au-nanorods. In line with these results, Mahmoud et al. observed that positively charged Au-nanorods aggregated extensively upon exposure to human skin compared to negatively and neutrally charged ones.[61] They attributed these findings to the adsorption of proteins released from the dermis layer to the surface of Au-nanorods. In this study, they prepared 49.5 x 12.0 nm Au-nanorods capped with four different surface ligands: cetyltrimethylammonium (CTAB), poly acrylic acid (PAA), poly(allylamine hydrochloride) (PAH), and methoxy-polyethylene glycol-thiol (m-PEG-SH). Conversely, Hao et al. also investigated the influence of the surface charge on the skin penetration of spherical AuNPs using human reconstructed 3D Episkin model.[62] In this study, three different surfaces charged 5 nm-AuNPs capped with citrate (negative), PVP (neutral), and CTAB (positive) were tested. They observed that, although all AuNPs induced the phase change of lipid lamella and pass through the epidermis, positively charged ones exhibited the most efficient skin penetration through both the paracellular routes and the transcellular pathway, when compared to neutrally or negatively charged NPs.

An interesting alternative for stabilizing NPs surface is the PEGylation, which is a commonly used approach for improving the drug and gene delivery efficiency of NP-based systems to target cells and tissues.[63] Hsiao and co-workers employed this

approach to investigate the positive effects of polyethylene glycol (HS-PEG-COOH) and HS-PEG-oleyamine (OAm) functionalization on the skin permeation of spherical 10 nm AuNPs.[64] Using an *in vivo* rat model, they showed that PEG- and PEG-OAm-functionalized AuNPs were able to overcome the skin barrier and deposit in the deeper subcutaneous adipose tissue. Moreover, the follicular deposition of AuNPs increased 2-fold after PEG-OAm functionalization, demonstrating a preferential accumulation mediated by the stabilizing ligand. Mahmoud et al. evaluated the preferential accumulation of Au-nanorods into abdominal human skin hair follicles.[65] To this end, they prepared 11.4 x 46.6 nm Au-nanorods with five different surface chemistries (i.e. neutral, anionic, cationic, and hydrophobic), such as CTAB, PAA, methoxy-polyethylene glycol-thiol (m-PEG-SH), PEG-Cystamine, and polystyrene (PS). They observed that the lipophilic properties of sebum-rich hair follicles enhanced the accumulation of hydrophobic PS-Au-nanorods into hair follicles, while neutral m-PEG-S-Au-nanorods were distributed into all skin compartments, especially the dermis, which exhibits hydrophilic characteristics. In addition, both charged Au-nanorods showed a negligible percentage of penetration into any of the skin compartments.

3. Bioconjugated plasmonic NPs for transdermal delivery of different cargoes.

A seminal study on the development of bioconjugated plasmonic NPs for enhancing the skin penetration of different cargoes was reported in 2010 by Huang and co-workers.[56] They demonstrated a significant enhance of the transdermal delivery of protein-drugs by co-administration with 5 nm PVP-capped AuNPs. This fact was attributed to the nano-bio interaction with skin lipids, which allowed a reversible openings of the stratum corneum. Thus, this work provided a simple and efficient NPs-mediated method for overcoming the skin barrier for percutaneous protein drug delivery. Labala et al. reported the first bioconjugated plasmonic NPs for iontophoretic transdermal delivery of imatinib mesylate to treat melanoma, using a LbL assembly approach.[66] This LbL polymer capped AuNPs contained PVP and polyethylene imine (PEI), and was subsequently coated with anionic poly(styrenesulfonate) (PSS) and cationic PEI for the drug loading. The resulting bioconjugated nanosystem showed an average particle size and a zeta-potential of 98 ± 4 nm and $+ 32 \pm 1$ mV, respectively, and a shift of the SPR wavelength from 518 to 530 nm. The *in vitro* skin penetration studies were performed on excised

porcine ear, and they demonstrated that iontophoresis application enhanced the skin penetration of imatinib mesylate loaded AuNP by 6.2-fold compared to passive application.

Bessar et al. prepared a water-soluble sodium 3-mercapto-1-propansulfonate(3MPS)-capped AuNPs, which were loaded with methotrexate (MTX) via electrostatic adsorption. The resulting Au-3MPS@MTX conjugate showed an average size and a zeta-potential of ~ 5 nm and -32 ± 1 mV, respectively. Then, it was topically administrated on C57BL/6 mouse normal skin in order to assess the absorption behaviour. In vitro and in vivo studies showed that MTX-conjugated AuNPs was much more efficient than MTX alone, suggesting this nanosystem as a potential candidate for topical treatment of psoriasis, see Figure 4A.[67]




Figure 4. A) Electron microscopy pictures of normal human keratinocytes. a) control b) treated cells with bioconjugated plasmonic NPs.[67] Copyright from Elsevier, 2016. B) Wounds treated with non-coated and bioconjugated plasmonic NPs, showing the absence of granulation tissue.[68] Copyright from Elsevier, 2018.

An interesting application of bioconjugated plasmonic NPs for enhance transdermal gene delivery was the reported by Niu and co-workers.[69] In order to facilitate the skin penetration of plasmid DNA (i.e. pDNA encoding miRNA-221 inhibitor -Mi221-) deeply into the melanoma tissues, they synthesized an 20-25 nm conjugated AuNPs containing a cell-penetrating TAT peptide and the cationic PEI that could compact the pDNAs into cationic nanocomplexes (i.e. zeta-potential $\sim +35$ mV). They demonstrated that the resulting plasmonic bioconjugates can penetrate through the intact stratum corneum without any additional enhancement physical method. This study proposed a novel topical gene therapy strategy for skin cancer with great priority to reverse both the progression and metastasis of advanced melanoma. Chen et al. fabricated a bioconjugate plasmonic NPs for the transdermal delivery of the vascular endothelial growth factor (VEGF) in wound repair.[70] To that end, they performed the bioconjugation of AuNP-PEG-COOH with VEGF through carbodiimide bonds, obtaining a negative surface charged nanosystem, whose absorption capability was evaluated by a mouse skin model. After the treatment, they observed not only the presence of VEGF into the dermis but also its effect for promoting the angiogenesis, demonstrating that in this case the binding of protein biological factors to AuNPs could preserve the activity of the protein. Other study reported by Safwat el al., who fabricated AuNPs capped with benzalkonium chloride and with PEI for enhanced loading and skin permeability of 5-fluorouracil (i.e. 5-FU/BC-AuNPs and 5-FU/PEI-AuNPs, respectively).[71] They performed ex vivo permeability studies of different 5-FU preparations using mice skin, demonstrating that the permeability of 5-FU was significantly higher for drug-loaded AuNPs compared with the other tested 5-FU samples. This same research group also prepared 5-FU loaded through ionic interactions onto CTAB capped AuNPs, and the resulting nanocomposite was incorporated into gel and cream bases to evaluate its permeability both ex vivo in mice dorsal skin and in vivo A431 tumor-bearing mice.[72] They observed that the nanoformulation provided around 2-fold higher permeability through mice skin compared with free 5-FU gel and cream formulations, and achieved 6.8- and 18.4-fold lower tumour volume compared with the untreated control with the gel- and the cream-based nanoformulation, respectively. On the other hand, Boca et al. performed the first preliminar study to evaluate the potential use under dermatological conditions of Ruxolitinib-conjugated 15 nm AuNPs as alternative for treating alopecia.[73] Using in vitro preclinical setting, they showed that AuNPs@TWEEN-20@Ruxolitinib inhibited the

proliferation of fibroblasts by inhibiting JAK2 protein, suggesting it as a potential strategy to treat alopecia.

Another novel and alternative administration strategy of bioconjugated plasmonic NPs was proposed by Anirudhan et al., who fabricated a nanocomposite film containing methacrylate-stitched β -cyclodextrin embedded with AuNPs and hydrophobic titanium nanotube (TNT) and tested the transdermal delivery of ibuprofen through in vitro rat skin.[74] They showed that the resulting film exhibited an improved drug-delivery performance, which was attributed to synergistic action of AuNP and hydrophobic TNT. They proposed this nanocomposite film as an alternative skin permeation strategy for transdermal drug delivery. Similarly, this same research group proposed a polyelectrolyte membrane fabricated with guar gum, poly(vinyl alcohol) and a nanogold-nanocellulose composite for the topical administration of diltiazem hydrochloride. In vivo analysis on human skin of this film were performed, suggesting its potential use for transdermal drug delivery.[75]

Pan et al. explored the effects on wound healing of keratinocyte growth factor (KGF) cross-linked to AuNPs.[68] Using an animal full-thickness wound model, they showed that KGF-AuNPs were more favourable to wound healing than bare AuNPs or KGF, thus being proposed as a promising wound healing drug for clinical application, see Figure 4B. Crisan et al. evaluated the impact on psoriatic inflammation of AgNPs and AuNPs complexed with *Cornus mas* (i.e. polyphenols-rich extracts) by using an in vitro model based on pro-inflammatory macrophages.[76] The results obtained from all the performed in vitro analysis suggested that these bioconjugated plasmonic NPs provided an efficient tool for modern psoriasis therapy, circumventing immunosuppression-related side effects of biologicals. In another study, Wang et al. fabricated an antimicrobial peptide (LL37) grafted ultra-small AuNPs (AuNPs@LL37, ~ 7 nm), which was combined with pro-angiogenic (VEGF) plasmids to analyse its potential use for the topical treatment of diabetic wounds with or without bacterial infection.[77] The resulting bioconjugate (AuNPs@LL37/pDNAs) combined the advantages of cationic surface charged NPs that condense DNA with those of antibacterial peptides and enhance the cellular and nucleus entry to achieve high gene delivery efficiency. AuNPs@LL37/pDNAs were shown to greatly improve the gene transfection efficiency in keratinocytes compared with pristine AuNPs/pDNAs, exhibiting a similar expression to Lipo2000/pDNAs (a well-known highly efficient gene transfection agent), whilst displaying higher antibacterial ability.

Thus, this bioconjugated plasmonic NPs were suggested as a suitable strategy for treating chronic diabetic wounds.

More recently, Fratoddi et al. analysed the effects of AuNPs functionalized with 3-mercaptopropylsulfonate (AuNPs-3MPS) and loading MTX topically administered in vitro on skin model and in vivo on imiquimod-induced psoriasis-like mice model.[78] They showed that the treatment with this system was able to induce a reduction of keratinocytes hyperproliferation, epidermal thickness and also inflammatory infiltrate in the used in vivo model. Hernández-Martínez et al. synthesized and evaluated a nanocomposite of AuNPs functionalized with calreticulin.[79] Using in vitro and in vivo wound healing mice models of diabetes, they assessed the ability of the nanocomposite to promote proliferation and migration. Their results confirmed the utility of this bioconjugated plasmonic NPs (AuNPs-calreticulin) as potential treatment for wound healing of diabetic ulcers.

In the case of AgNPs-based bioconjugates, Mandal and co-workers fabricated a nanocomposite hydrogel comprised of in situ formed Ag nanowires (AgNWs) deposited chemically cross-linked carboxymethyl cellulose (CMC), which demonstrated superior efficacy as transdermal anticancer drug-curcumin carrier.[80] This plasmonic bioconjugate had the capability to encapsulate both hydrophobic/hydrophilic transdermal drugs. The in vitro experiments suggested that the presence of AgNWs on cross-linked CMC enhanced both the penetration power of nanocomposite hydrogel and the drug release in sustained manner. Whilst the ex vivo rat skin permeation analysis confirmed that the drug delivery through the nanocomposite hydrogel was permeable through the rat skin in controlled fashion, killing efficiently the MG 63 cancer cells.

Table 1 summarises the bioconjugated plasmonic NPs cited in this review, indicating both the loaded active molecule and the potential application.

Table 1. Representative cargoes in through bioconjugated plasmonic NPs for skin diseases treatment.

Active molecule	Cargo type	Activity/Application	NPs	Ref.
Imatinib mesylate	Drug	Anticancer	Au	[66]
Methotrexate (MTX)	Drug	Anti-inflammatory (psoriasis)	Au	[67,78]
microRNA mir-221	Gene	Tumour suppressor (melanoma)	Au	[69]
Vascular endothelial growth factor (VEGF)	Protein	Wound repair	Au	[70]
Ibuprofen	Drug	Anti-inflammatory	Au	[74]
Diltiazem hydrochloride	Drug	Vasodilator	Au	[75]
5-fluorouracil (5-FU)	Drug	Anticancer	Au	[71,72]
Ruxolitinib	Drug	Anti-alopecia	Au	[73]
Keratinocyte growth factor (KGF)	Protein	Wound repair	Au	[68]
Polyphenols-rich extracts (Cornus mas)	Natural extract	Anti-inflammatory (psoriasis)	Au & Ag	[76]
Antimicrobial peptide LL-37 & pDNA: Pro-angiogenic (VEGF) plasmids	Protein & Gene	Diabetic wound healing	Au	[77]
Calreticulin	Protein	Diabetic wound healing	Au	[79]
Curcumin	Natural extract	Anticancer	Ag	[80]

Conclusions

Bioconjugated plasmonic NPs are a promising approach for topical administration of different cargoes for several diseases. The excellent biocompatibility and the readily adjustable physical and chemical features of the plasmonic NPs are highly attractive options for purposefully designed nanomaterials aimed at biomedical applications. Several examples have been presented herein, illustrating the wide range of cargoes and functionalization strategies that might be included when designing a bioconjugated plasmonic NPs. Different physical and chemical parameters should be taken into account when analysing the effect of plasmonic NPs in human skin. While the chemical routes for

obtaining on-demand plasmonic NPs are relatively well-established and a large number of simple and reproducible experimental protocols are available, the main frontier for mass usage is still a correct assessment of the toxicity of the NPs. Provided a relevant model for human skin, the experimental conditions for studying location and local concentration of plasmonic NPs greatly differs from those found in the synthesis laboratories. Therefore, this fruitful field of research requires more efforts are to fully understand the penetration mechanism of these bioconjugated plasmonic NPs, enabling the decrease of associated toxicity and the potential long-term environmental impacts. In view of the latest contribution to the field, we speculate that a reliable framework will be available in the short term, enabling the second wave of research for directed synthesis and application of plasmonic NPs at in vivo conditions.

Acknowledgements

We apologize to authors whose work could not be included in this review due to space restrictions. Support from the Ministry of Science, Innovation and Universities of Spain is acknowledged through the MANA project CTQ2017-83961-R. J.J.G.-C. acknowledges the Ministry of Science, Innovation and Universities of Spain for a “Ramon y Cajal” contract (#RyC-2014-14956). M. C. thanks the “Plan Propio de Investigación” from the Universidad de Córdoba (UCO) and the “Programa Operativo de fondos FEDER Andalucía” for its financial support through both postdoctoral contracts (Modality 5.2.A).

References

1. Huang X, Jain PK, El-Sayed IH, El-Sayed MA (2007) Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. *Nanomedicine* 2:681–693. <https://doi.org/10.2217/17435889.2.5.681>
2. Giner-Casares JJ, Henriksen-Lacey M, Coronado-Puchau M, Liz-Marzán LM (2016) Inorganic nanoparticles for biomedicine: where materials scientists meet medical research. *Mater Today* 19:19–28. <https://doi.org/10.1016/j.mattod.2015.07.004>
3. Ogarev VA, Rudoi VM, Dement'eva O V. (2018) Gold Nanoparticles: Synthesis, Optical Properties, and Application. *Inorg Mater Appl Res* 9:134–140.

<https://doi.org/10.1134/S2075113318010197>

4. Shukla R, Bansal V, Chaudhary M, et al (2005) Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the Cellular Compartment: A Microscopic Overview. *Langmuir* 21:10644–10654.
<https://doi.org/10.1021/la0513712>
5. Burduşel A-C, Gherasim O, Grumezescu AM, et al (2018) Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview. *Nanomaterials* 8:681. <https://doi.org/10.3390/nano8090681>
6. Woehrle GH, Brown LO, Hutchison JE (2005) Thiol-Functionalized, 1.5-nm Gold Nanoparticles through Ligand Exchange Reactions: Scope and Mechanism of Ligand Exchange. *J Am Chem Soc* 127:2172–2183.
<https://doi.org/10.1021/ja0457718>
7. Alba-Molina D, Puente Santiago AR, Giner-Casares JJ, et al (2019) Tailoring the ORR and HER electrocatalytic performances of gold nanoparticles through metal–ligand interfaces. *J Mater Chem A* 7:20425–20434.
<https://doi.org/10.1039/C9TA05492H>
8. Berry V, Saraf RF (2005) Self-Assembly of Nanoparticles on Live Bacterium: An Avenue to Fabricate Electronic Devices. *Angew Chemie Int Ed* 44:6668–6673. <https://doi.org/10.1002/anie.200501711>
9. Chen Y-S, Hong M-Y, Huang GS (2012) A protein transistor made of an antibody molecule and two gold nanoparticles. *Nat Nanotechnol* 7:197–203.
<https://doi.org/10.1038/nnano.2012.7>
10. Alba-Molina D, Rodriguez-Padron D, Puente Santiago ARR, et al (2018) Mimicking the bioelectrocatalytic function of recombinant CotA laccase via electrostatically self-assembled nanobioconjugates. *Nanoscale*.
<https://doi.org/10.1039/C8NR06001K>
11. Alba-Molina D, Puente Santiago AR, Giner-Casares JJ, et al (2019) Citrate-Stabilized Gold Nanoparticles as High-Performance Electrocatalysts: The Role of Size in the Electroreduction of Oxygen. *J Phys Chem C* 123:9807–9812.
<https://doi.org/10.1021/acs.jpcc.9b00249>

12. Upadhyayula VKK (2012) Functionalized gold nanoparticle supported sensory mechanisms applied in detection of chemical and biological threat agents: A review. *Anal Chim Acta* 715:1–18. <https://doi.org/10.1016/j.aca.2011.12.008>
13. Draz MS, Shafiee H (2018) Applications of gold nanoparticles in virus detection. *Theranostics* 8:1985–2017. <https://doi.org/10.7150/thno.23856>
14. Huang X, El-Sayed MA (2010) Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy. *J Adv Res* 1:13–28. <https://doi.org/10.1016/j.jare.2010.02.002>
15. Vines JB, Yoon J-H, Ryu N-E, et al (2019) Gold Nanoparticles for Photothermal Cancer Therapy. *Front Chem* 7:. <https://doi.org/10.3389/fchem.2019.00167>
16. Dreaden EC, Austin LA, Mackey MA, El-Sayed MA (2012) Size matters: gold nanoparticles in targeted cancer drug delivery. *Ther Deliv* 3:457–478. <https://doi.org/10.4155/tde.12.21>
17. Farooq MU, Novosad V, Rozhkova EA, et al (2018) Gold Nanoparticles-enabled Efficient Dual Delivery of Anticancer Therapeutics to HeLa Cells. *Sci Rep* 8:2907. <https://doi.org/10.1038/s41598-018-21331-y>
18. Cole LE, Ross RD, Tilley JM, et al (2015) Gold nanoparticles as contrast agents in x-ray imaging and computed tomography. *Nanomedicine* 10:321–341. <https://doi.org/10.2217/nmm.14.171>
19. Mahan MM, Doiron AL (2018) Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology. *J Nanomater* 2018:1–15. <https://doi.org/10.1155/2018/5837276>
20. Gong P, Li H, He X, et al (2007) Preparation and antibacterial activity of Fe₃O₄@Ag nanoparticles. *Nanotechnology* 18:285604. <https://doi.org/10.1088/0957-4484/18/28/285604>
21. Durán N, Durán M, de Jesus MB, et al (2016) Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity. *Nanomedicine Nanotechnology, Biol Med* 12:789–799. <https://doi.org/10.1016/j.nano.2015.11.016>
22. Samberg ME, Oldenburg SJ, Monteiro-Riviere NA (2010) Evaluation of Silver

- Nanoparticle Toxicity in Skin in Vivo and Keratinocytes in Vitro. *Environ Health Perspect* 118:407–413. <https://doi.org/10.1289/ehp.0901398>
23. Brandt O, Mildner M, Egger AE, et al (2012) Nanoscale silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine. *Nanomedicine Nanotechnology, Biol Med* 8:478–488. <https://doi.org/10.1016/j.nano.2011.07.005>
 24. Pegoraro C, MacNeil S, Battaglia G (2012) Transdermal drug delivery: from micro to nano. *Nanoscale* 4:1881. <https://doi.org/10.1039/c2nr11606e>
 25. Amjadi M, Mostaghaci B, Sitti M (2017) Recent Advances in Skin Penetration Enhancers for Transdermal Gene and Drug Delivery. *Curr Gene Ther* 17:. <https://doi.org/10.2174/1566523217666170510151540>
 26. Prausnitz MR, Mitragotri S, Langer R (2004) Current status and future potential of transdermal drug delivery. *Nat Rev Drug Discov* 3:115–124. <https://doi.org/10.1038/nrd1304>
 27. Patzelt A, Lademann J (2013) Drug delivery to hair follicles. *Expert Opin Drug Deliv* 10:787–797. <https://doi.org/10.1517/17425247.2013.776038>
 28. Lauterbach A, Müller-Goymann CC (2015) Applications and limitations of lipid nanoparticles in dermal and transdermal drug delivery via the follicular route. *Eur J Pharm Biopharm* 97:152–163. <https://doi.org/10.1016/j.ejpb.2015.06.020>
 29. Vogt A, Wischke C, Neffe AT, et al (2016) Nanocarriers for drug delivery into and through the skin — Do existing technologies match clinical challenges? *J Control Release* 242:3–15. <https://doi.org/10.1016/j.jconrel.2016.07.027>
 30. Larese Filon F, Mauro M, Adami G, et al (2015) Nanoparticles skin absorption: New aspects for a safety profile evaluation. *Regul Toxicol Pharmacol* 72:310–322. <https://doi.org/10.1016/j.yrtph.2015.05.005>
 31. Núñez-Lozano R, Cano M, Pimentel B, de la Cueva-Méndez G (2015) ‘Smartening’ anticancer therapeutic nanosystems using biomolecules. *Curr Opin Biotechnol* 35:135–140. <https://doi.org/10.1016/j.copbio.2015.07.005>
 32. Campbell CSJ, Contreras-Rojas LR, Delgado-Charro MB, Guy RH (2012)

- Objective assessment of nanoparticle disposition in mammalian skin after topical exposure. *J Control Release* 162:201–207.
<https://doi.org/10.1016/j.jconrel.2012.06.024>
33. Zhou Y, Damasceno PF, Somashekar BS, et al (2018) Unusual multiscale mechanics of biomimetic nanoparticle hydrogels. *Nat Commun* 9:181.
<https://doi.org/10.1038/s41467-017-02579-w>
 34. Larese Filon F, D'Agostin F, Crosera M, et al (2009) Human skin penetration of silver nanoparticles through intact and damaged skin. *Toxicology* 255:33–37.
<https://doi.org/10.1016/j.tox.2008.09.025>
 35. Bianco C, Adami G, Crosera M, et al (2014) Silver percutaneous absorption after exposure to silver nanoparticles: A comparison study of three human skin graft samples used for clinical applications. *Burns* 40:1390–1396.
<https://doi.org/10.1016/j.burns.2014.02.003>
 36. Larese Filon F, Crosera M, Adami G, et al (2011) Human skin penetration of gold nanoparticles through intact and damaged skin. *Nanotoxicology* 5:493–501.
<https://doi.org/10.3109/17435390.2010.551428>
 37. Sonavane G, Tomoda K, Sano A, et al (2008) In vitro permeation of gold nanoparticles through rat skin and rat intestine: Effect of particle size. *Colloids Surfaces B Biointerfaces* 65:1–10. <https://doi.org/10.1016/j.colsurfb.2008.02.013>
 38. Raju G, Katiyar N, Vadukumpully S, Shankarappa SA (2018) Penetration of gold nanoparticles across the stratum corneum layer of thick-Skin. *J Dermatol Sci* 89:146–154. <https://doi.org/10.1016/j.jdermsci.2017.11.001>
 39. Rivera-Gil P, Jimenez De Aberasturi D, Wulf V, et al (2013) The Challenge To Relate the Physicochemical Properties of Colloidal Nanoparticles to Their Cytotoxicity. *Acc Chem Res* 46:743–749. <https://doi.org/10.1021/ar300039j>
 40. Avci P, Sadasivam M, Gupta A, et al (2013) Animal models of skin disease for drug discovery. *Expert Opin Drug Discov* 8:331–355.
<https://doi.org/10.1517/17460441.2013.761202>
 41. Arora S, Jain J, Rajwade JM, Paknikar KM (2008) Cellular responses induced by

- silver nanoparticles: In vitro studies. *Toxicol Lett* 179:93–100.
<https://doi.org/10.1016/j.toxlet.2008.04.009>
42. Liu DC, Raphael AP, Sundh D, et al (2012) The Human Stratum Corneum Prevents Small Gold Nanoparticle Penetration and Their Potential Toxic Metabolic Consequences. *J Nanomater* 2012:1–8.
<https://doi.org/10.1155/2012/721706>
 43. Cano M, Núñez-Lozano R, Lumbreras R, et al (2017) Partial PEGylation of superparamagnetic iron oxide nanoparticles thinly coated with amine-silane as a source of ultrastable tunable nanosystems for biomedical applications. *Nanoscale* 9:812–822. <https://doi.org/10.1039/C6NR07462F>
 44. Grzelczak M, Pérez-Juste J, Mulvaney P, Liz-Marzán LM (2008) Shape control in gold nanoparticle synthesis. *Chem Soc Rev* 37:1783.
<https://doi.org/10.1039/b711490g>
 45. Hühn J, Carrillo-Carrion C, Soliman MG, et al (2017) Selected Standard Protocols for the Synthesis, Phase Transfer, and Characterization of Inorganic Colloidal Nanoparticles. *Chem Mater* 29:399–461.
<https://doi.org/10.1021/acs.chemmater.6b04738>
 46. Sánchez-Iglesias A, Winckelmans N, Altantzis T, et al (2017) High-Yield Seeded Growth of Monodisperse Pentatwinned Gold Nanoparticles through Thermally Induced Seed Twinning. *J Am Chem Soc* 139:107–110.
<https://doi.org/10.1021/jacs.6b12143>
 47. Toy R, Peiris PM, Ghaghada KB, Karathanasis E (2014) Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. *Nanomedicine* 9:121–134. <https://doi.org/10.2217/nnm.13.191>
 48. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol* 33:941–951.
<https://doi.org/10.1038/nbt.3330>
 49. Wang W, Gaus K, Tilley RD, Gooding JJ (2019) The impact of nanoparticle shape on cellular internalisation and transport: what do the different analysis methods tell us? *Mater Horizons* 6:1538–1547.

<https://doi.org/10.1039/C9MH00664H>

50. Fernandes R, Smyth NR, Muskens OL, et al (2015) Interactions of Skin with Gold Nanoparticles of Different Surface Charge, Shape, and Functionality. *Small* 11:713–721. <https://doi.org/10.1002/sml.201401913>
51. Tak YK, Pal S, Naoghare PK, et al (2015) Shape-Dependent Skin Penetration of Silver Nanoparticles: Does It Really Matter? *Sci Rep* 5:16908. <https://doi.org/10.1038/srep16908>
52. Turkevich J, Kim G (1970) Palladium: Preparation and Catalytic Properties of Particles of Uniform Size. *Science* (80-) 169:873–879. <https://doi.org/10.1126/science.169.3948.873>
53. Kimling J, Maier M, Okenve B, et al (2006) Turkevich Method for Gold Nanoparticle Synthesis Revisited. *J Phys Chem B* 110:15700–15707. <https://doi.org/10.1021/jp061667w>
54. Labouta HI, Liu DC, Lin LL, et al (2011) Gold Nanoparticle Penetration and Reduced Metabolism in Human Skin by Toluene. *Pharm Res* 28:2931–2944. <https://doi.org/10.1007/s11095-011-0561-z>
55. Labouta HI, El-Khordagui LK, Kraus T, Schneider M (2011) Mechanism and determinants of nanoparticle penetration through human skin. *Nanoscale* 3:4989. <https://doi.org/10.1039/c1nr11109d>
56. Huang Y, Yu F, Park Y-S, et al (2010) Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. *Biomaterials* 31:9086–9091. <https://doi.org/10.1016/j.biomaterials.2010.08.046>
57. Hong S, Bielinska AU, Mecke A, et al (2004) Interaction of Poly(amidoamine) Dendrimers with Supported Lipid Bilayers and Cells: Hole Formation and the Relation to Transport. *Bioconjug Chem* 15:774–782. <https://doi.org/10.1021/bc049962b>
58. Kirjavainen M, Urtti A, Jääskeläinen I, et al (1996) Interaction of liposomes with human skin in vitro — The influence of lipid composition and structure. *Biochim Biophys Acta - Lipids Lipid Metab* 1304:179–189.

- [https://doi.org/10.1016/S0005-2760\(96\)00126-9](https://doi.org/10.1016/S0005-2760(96)00126-9)
59. Shanmugam S, Song C-K, Nagayya-Sriraman S, et al (2009) Physicochemical characterization and skin permeation of liposome formulations containing clindamycin phosphate. *Arch Pharm Res* 32:1067–1075.
<https://doi.org/10.1007/s12272-009-1713-0>
 60. Lee O, Jeong SH, Shin WU, et al (2013) Influence of surface charge of gold nanorods on skin penetration. *Ski Res Technol* 19:e390–e396.
<https://doi.org/10.1111/j.1600-0846.2012.00656.x>
 61. Mahmoud NN, Al-Qaoud KM, Al-Bakri AG, et al (2016) Colloidal stability of gold nanorod solution upon exposure to excised human skin: Effect of surface chemistry and protein adsorption. *Int J Biochem Cell Biol* 75:223–231.
<https://doi.org/10.1016/j.biocel.2016.02.020>
 62. Hao F, Jin X, Liu QS, et al (2017) Epidermal Penetration of Gold Nanoparticles and Its Underlying Mechanism Based on Human Reconstructed 3D Episkin Model. *ACS Appl Mater Interfaces* 9:42577–42588.
<https://doi.org/10.1021/acsami.7b13700>
 63. Suk JS, Xu Q, Kim N, et al (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Adv Drug Deliv Rev* 99:28–51.
<https://doi.org/10.1016/j.addr.2015.09.012>
 64. Tsai H-C, Hsiao PF, Peng S, et al (2016) Enhancing the in vivo transdermal delivery of gold nanoparticles using poly(ethylene glycol) and its oleylamine conjugate. *Int J Nanomedicine* 1867. <https://doi.org/10.2147/IJN.S102599>
 65. Mahmoud NN, Alkilany AM, Dietrich D, et al (2017) Preferential accumulation of gold nanorods into human skin hair follicles: Effect of nanoparticle surface chemistry. *J Colloid Interface Sci* 503:95–102.
<https://doi.org/10.1016/j.jcis.2017.05.011>
 66. Labala S, Mandapalli PK, Kurumaddali A, Venuganti VVK (2015) Layer-by-Layer Polymer Coated Gold Nanoparticles for Topical Delivery of Imatinib Mesylate To Treat Melanoma. *Mol Pharm* 12:878–888.
<https://doi.org/10.1021/mp5007163>

67. Bessar H, Venditti I, Benassi L, et al (2016) Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. *Colloids Surfaces B Biointerfaces* 141:141–147.
<https://doi.org/10.1016/j.colsurfb.2016.01.021>
68. Pan A, Zhong M, Wu H, et al (2018) Topical Application of Keratinocyte Growth Factor Conjugated Gold Nanoparticles Accelerate Wound Healing. *Nanomedicine Nanotechnology, Biol Med* 14:1619–1628.
<https://doi.org/10.1016/j.nano.2018.04.007>
69. Niu J, Chu Y, Huang Y-F, et al (2017) Transdermal Gene Delivery by Functional Peptide-Conjugated Cationic Gold Nanoparticle Reverses the Progression and Metastasis of Cutaneous Melanoma. *ACS Appl Mater Interfaces* 9:9388–9401.
<https://doi.org/10.1021/acsami.6b16378>
70. Chen Y, Wu Y, Gao J, et al (2017) Transdermal Vascular Endothelial Growth Factor Delivery with Surface Engineered Gold Nanoparticles. *ACS Appl Mater Interfaces* 9:5173–5180. <https://doi.org/10.1021/acsami.6b15914>
71. Safwat MA, Soliman GM, Sayed D, Attia MA (2017) Gold nanoparticles capped with benzalkonium chloride and poly (ethylene imine) for enhanced loading and skin permeability of 5-fluorouracil. *Drug Dev Ind Pharm* 43:1780–1791.
<https://doi.org/10.1080/03639045.2017.1339082>
72. Safwat MA, Soliman GM, Sayed D, Attia MA (2018) Fluorouracil-Loaded Gold Nanoparticles for the Treatment of Skin Cancer: Development, in Vitro Characterization, and in Vivo Evaluation in a Mouse Skin Cancer Xenograft Model. *Mol Pharm* 15:2194–2205.
<https://doi.org/10.1021/acs.molpharmaceut.8b00047>
73. Boca S, Berce C, Jurj A, et al (2017) Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia? *Med Hypotheses* 109:42–45. <https://doi.org/10.1016/j.mehy.2017.09.023>
74. Anirudhan TS, Nair SS, Sasidharan A V. (2017) Methacrylate-Stitched β -Cyclodextrin Embedded with Nanogold/Nanotitania: A Skin Adhesive Device for Enhanced Transdermal Drug Delivery. *ACS Appl Mater Interfaces* 9:44377–

44391. <https://doi.org/10.1021/acsami.7b16686>
75. Anirudhan TS, Nair SS, Sekhar. V C (2017) Deposition of gold-cellulose hybrid nanofiller on a polyelectrolyte membrane constructed using guar gum and poly(vinyl alcohol) for transdermal drug delivery. *J Memb Sci* 539:344–357. <https://doi.org/10.1016/j.memsci.2017.05.054>
 76. Crisan D, Scharffetter-Kochanek K, Crisan M, et al (2018) Topical silver and gold nanoparticles complexed with *Cornus mas* suppress inflammation in human psoriasis plaques by inhibiting NF- κ B activity. *Exp Dermatol* 27:1166–1169. <https://doi.org/10.1111/exd.13707>
 77. Wang S, Yan C, Zhang X, et al (2018) Antimicrobial peptide modification enhances the gene delivery and bactericidal efficiency of gold nanoparticles for accelerating diabetic wound healing. *Biomater Sci* 6:2757–2772. <https://doi.org/10.1039/C8BM00807H>
 78. Fratoddi I, Benassi L, Botti E, et al (2019) Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model. *Nanomedicine Nanotechnology, Biol Med* 17:276–286. <https://doi.org/10.1016/j.nano.2019.01.006>
 79. Hernández Martínez SP, Rivera González TI, Franco Molina MA, et al (2019) A Novel Gold Calreticulin Nanocomposite Based on Chitosan for Wound Healing in a Diabetic Mice Model. *Nanomaterials* 9:75. <https://doi.org/10.3390/nano9010075>
 80. Mandal B, Rameshbabu AP, Soni SR, et al (2017) In Situ Silver Nanowire Deposited Cross-Linked Carboxymethyl Cellulose: A Potential Transdermal Anticancer Drug Carrier. *ACS Appl Mater Interfaces* 9:36583–36595. <https://doi.org/10.1021/acsami.7b10716>